Genetics & Serum Database of IBS

Condition: Irritable bowel syndrome

Eligibility

Key Inclusion Criteria (IBS participants):

  • Must meet Rome II criteria
    • At least 12 weeks of abdominal discomfort or pain that has two of three features:
      • Relieved with defecation and/or
      • Onset associated with a change in frequency of stool and/or
      • Onset associated with a change in form (appearance) of stool

Key Exclusion Criteria

  • History of abdominal surgery such as bowel resection
  • History of other known GI disease or inflammatory bowel diseases
  • History of abdominal adhesions

Full Study Name

Genetics and Serum Database of Patients With Irritable Bowel Syndrome
(IRB no. 14738)

The purpose of this study is to understand the causes of irritable bowel syndrome (IBS) by looking at both genetic and immunologic mechanisms. Examination of DNA will enable researchers to understand which gene(s) contributes to the development of IBS. In this study, researchers aim to create a bank of blood for future genetic analyses to identify specific genes responsible for IBS development. They also aim to identify possible tests, such as looking for antibodies (which act as an immune defense) to food poisoning toxins, to help diagnose and evaluate the likelihood that they lead to IBS.

Principal Investigator

Mark Pimentel, MD

Contact
Kathleen-Shari Chua
Email: kathleenshari.chua@cshs.org

Tahli Singer-Englar
Phone: 310-423-3792
Email: tahli.singerenglar@cshs.org